Acta Scientific Gastrointestinal Disorders (ASGIS)(ISSN: 2582-1091)

Case Report Volume 5 Issue 5

A Case Report of a Child with Langerhans Cell Histiocytosis

Srushti Gandhi1*, Rashid Merchant2 and Snehal Mallakmir2

1Department of Paediatrics, Nanavati Super Specialty Hospital, Mumbai, Maharashtra, India
2Department of Genetics, Nanavati Super Specialty Hospital, Mumbai, Maharashtra, India

*Corresponding Author: Srushti Gandhi, Department of Paediatrics, Nanavati Super Specialty Hospital, Mumbai, Maharashtra, India.

Received: March 04, 2022; Published: April 28, 2022


Langerhans cell histiocytosis (LCH) is a rare clonal disease of the monocyte-macrophage system, comprising of uncontrolled proliferation of CD1a+/CD207+ dendritic cells (DCs). It has a wide range of symptomatology making early diagnosis and intervention extremely challenging. LCH may range from mild single system involvement with isolated skin or bone lesions to life-threatening multi-system involvement. Furthermore, when risk organs are involved, even with aggressive treatment, 10-year survival rates are only 50%, further emphasizing the need for maintaining a high index of suspicion and early intervention. We present the case of a 2-year-old girl who arrived at our clinic with a painless lump over the head following a trivial head injury, and on further evaluation was found to have histopathologically confirmed multisystemic LCH. Response to treatment has been favourable.

Keywords: Langerhans Cell Histiocytosis; CD1a+/CD207+; Monocyte-Macrophage System; Litterer Siwe Disease; Hand-Schüller-Christian Disease


  1. Haupt R., et al. “Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patient till age of 18 years”. Pediatric Blood Cancer 60 (2013): 175-184. 
  2. Emile JF., et al. “Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages”. Blood 127.22 (2016): 2672-2681. 
  3. Minkov M. “Multisystem Langerhans cell histiocytosis in children. Current treatment and future directions”. Pediatric Drugs 13 (2011): 75-86. 
  4. Margo CE and Goldman DR. “Langerhans cell histiocytosis”. Survey of Ophthalmology 53 (2008): 332-358. 
  5. Grana N. “Langerhans cell histiocytosis”. Cancer Control 21 (2014): 328-334. 
  6. Postini AM., et al. “Langerhans cell histiocytosis: 40 years’ experience”. Pediatric Hematology and Oncology 34 (2012): 353-358. 
  7. Minkov M., et al. “Langerhans cell histiocytosis - Histiocyte Society Evaluation and Treatment Guidelines”. Protocol (2009)
  8. Abla O., et al. “Langerhans cell histiocytosis: current concepts and treatments”. Cancer Treatment Reviews 36 (2010): 354-359. 
  9. Donadieu J., et al. “Medical management of Langerhans cell histiocytosis from diagnosis to treatment”. Expert Opinion on Pharmacotherapy 13 (2012): 1309-1322. 
  10. Windebank K and Naduri V. “Langerhans cell histiocytosis”. Archives of Disease in Childhood 94 (2009): 904-908.
  11. Krooks J., et al. “Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up”. Journal of the American Academy of Dermatology 78.6 (2018): 1035-1044.
  12. Gadner H., et al. “A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis”. The Journal of Pediatrics 138.5 (2001): 728-734.
  13. Arkader A., et al. “Primary Musculoskeletal Langerhans Cell Histiocytosis in Children: An Analysis for a 3-Decade Period”. Journal of Pediatric Orthopaedics 29.2 (2009): 201-207.
  14. Cochrane Central Register of Controlled Trials. “LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis” 5 (2018).


Citation: Srushti Gandhi., et al. “A Case Report of a Child with Langerhans Cell Histiocytosis". Acta Scientific Gastrointestinal Disorders 5.5 (2022): 31-36.


Copyright: © 2022 Srushti Gandhi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US